Abbott: AIDS group lawsuit attracts negative publicity

Abbott Laboratories has sued a French AIDS activist group, Act Up Paris, for launching a cyber attack against its website. This comes as a surprise to the industry which, after years of negative publicity generated by AIDS activists, is investing a great deal of effort in working with patient advocacy groups.

Published By Datamonitor

Acambis: leading the pack on West Nile fever vaccine

Concern is rising in parts of the US that a West Nile fever outbreak could cause an epidemic worse than that experienced in 2004, due to a wet spring and diminishing immunity in the bird population. The increasing impact of the West Nile Virus since its arrival in the US in 2000 highlights the need for a preventative vaccine, with Acambis [ACM.L] leading the race to bring one to market.

Published By Datamonitor

Advanced Life Sciences: aiming for second place with cethromycin

Published By Datamonitor

AIDS 2010: promising developments for novel HIV agents and strategies

Given the abundance of therapeutic options for HIV treatment, companies are increasingly looking to simplify therapy through the development of cross-class combinations and nucleoside-sparing strategies to minimize toxicity. Many of the pipeline drugs highlighted at this year's International AIDS Conference brought this new direction of development into focus.

Published By Datamonitor

AIDS wasting: US physicians three times more likely to treat than European physicians

Published By Datamonitor

AIDS wasting: US physicians three times more likely to treat than European physicians

Published By Datamonitor

AIDS: European incidence falling 3.9% per year

Published By Datamonitor

AIDS: high price to pay

In setting a high price for Fuzeon, Roche has added more questions to the controversy over the cost of AIDS drugs. Will healthcare payors in western nations be able to afford the treatment, and will it open the door to still more expensive drugs in the future? Just as importantly, are manufacturers in danger of pricing themselves out of the market?

Published By Datamonitor

Anadys: hepatitis C grant should boost research

The German government has awarded US-based biotech company Anadys a grant to identify proteins involved in hepatitis C transmission. Anadys' novel approach to drug development could well result in the development of more effective products, which would enhance the company's position in the anti-infectives field.

Published By Datamonitor

Antibacterials: narrow-spectrum strategy could change market

Researchers from the Royal Free Hospital have found that cutting down the use of broad spectrum antimicrobial agents can lead to a reduction in infections caused by Clostridium difficile. A wider adoption of this approach could reduce the market potential for broad spectrum agents significantly.

Published By Datamonitor